A comparison of vilanterol/Fluticasone furoate with Formoterol/Budesonide in the management of bronchial asthma

A comparative study of Vilanterol/Fluticasone furoate with Formoterol/Budesonide in the management of stable bronchial asthma - nil

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/03/064848

Enrollment

Registered

2024-03-27

Start date

Unknown

Completion date

Unknown

Last updated

2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J00-J99- Diseases of the respiratory system Health Condition 2: J453- Mild persistent asthma

Interventions

Intervention1: vilanterol/fluticasone furoate 25/100 mcg od for 3months: formoterol/budesonide 6/200 mcg bd for 3 months Intervention2: vilanterol/fluticasone furoate: 25/100 mcg OD for 3 months Contr

Eligibility

Inclusion criteria

Inclusion criteria: 1. patients with stable bronchial asthma 2. patients who already receiving prescription with formoterol /budesonide

Exclusion criteria

Exclusion criteria: 1. patients with asthma /copd overlap 2. patients with bronchiectasis 3. patients with allergic bronchopulmonary aspergillosis 4.history of smoking 5.pregnancy

Design outcomes

Primary

Measure	Time frame
To assess the therapeutic effectiveness of Vilanterol/Fluticasone furoate with Formoterl/Budesonide by monitoring pulmonary function test (spirometry) FVC(L),%FVC,FEV1(L),%FEV1,FEV1/FVC,FEF25-75%Timepoint: In the initial ,patients FVC,%FVC ,FEV1,FEV1/FVC ,FEF25-75% will be evaluated ,mean changes in the parameters observed at 4th week,8th week ,12th week	—

Secondary

Measure	Time frame
Quality of Life assessed by ACQ5 Questionnaire,ACT Scores & Adherence Barrier SurveyTimepoint: 6 months	—

Countries

India

Contacts

Public ContactSundari V

SRM College of Pharmacy ,SRM Institute of Science and Technology

jagadeem1@srmist.edu.in7449277556

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026